134 related articles for article (PubMed ID: 18024821)
21. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population.
Azad RV; Khan MA; Chanana B; Azad S
Jpn J Ophthalmol; 2008; 52(1):52-6. PubMed ID: 18369701
[TBL] [Abstract][Full Text] [Related]
24. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
Bakri SJ; Couch SM; McCannel CA; Edwards AO
Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
[TBL] [Abstract][Full Text] [Related]
25. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
Rosenfeld PJ; Moshfeghi AA; Puliafito CA
Ophthalmic Surg Lasers Imaging; 2005; 36(4):331-5. PubMed ID: 16156152
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
Bom Aggio F; Eid Farah M; Melo GB
Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
[No Abstract] [Full Text] [Related]
27. Multifocal electroretinogram findings after intravitreal bevacizumab injection in choroidal neovascularization of age-related macular degeneration.
Park JY; Kim SH; Park TK; Ohn YH
Korean J Ophthalmol; 2011 Jun; 25(3):161-5. PubMed ID: 21655040
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.
Parodi MB; Iacono P; Kontadakis DS; Zucchiatti I; Cascavilla ML; Bandello F
Arch Ophthalmol; 2010 Sep; 128(9):1100-3. PubMed ID: 20837791
[TBL] [Abstract][Full Text] [Related]
29. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration.
Guthoff R; Guthoff T; Meigen T; Goebel W
Retina; 2011 Jan; 31(1):36-40. PubMed ID: 20921929
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Spandau UH; Jonas JB
Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
[No Abstract] [Full Text] [Related]
33. Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab).
Ehmann D; García R
Can J Ophthalmol; 2010 Feb; 45(1):36-40. PubMed ID: 20130708
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
[TBL] [Abstract][Full Text] [Related]
35. Extrafoveal choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab.
Mones JM; Lopez MA; Prieto JA; Rodriguez JP
Ophthalmic Surg Lasers Imaging; 2007; 38(3):226-8. PubMed ID: 17552389
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
Bashshur ZF; Schakal A; Hamam RN; El Haibi CP; Jaafar RF; Noureddin BN
Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab combined with infliximab in the treatment of choroidal neovascularization secondary to age-related macular degeneration: case report series.
Freitas LG; Isaac DL; Tannure WT; Gabriel LA; Reis RG; Rassi AR; Freitas CA; Ávila MP
Arq Bras Oftalmol; 2013; 76(3):180-4. PubMed ID: 23929080
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
Chen CY; Wong TY; Heriot WJ
Am J Ophthalmol; 2007 Mar; 143(3):510-2. PubMed ID: 17317398
[TBL] [Abstract][Full Text] [Related]
40. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
Lazic R; Gabric N
Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
